



# FINANCIAL TEAR SHEET

## CORPORATE PROFILE

At PRA Health Sciences, we work side-by-side with our clients, to move drug discovery forward, and to help them develop life-saving and life-improving drugs. For more than 30 years, we've been helping to bring to market everything from niche treatments and therapies to blockbuster drugs. Providing comprehensive Phase I-IV biopharmaceutical drug development in over 100 countries, we are dedicated to being innovative, and to delivering unmatched scientific expertise that improves the drug development process.

We help change people's lives for the better every single day. It's what we are passionate about.

## STOCK QUOTE & CHART

PRAH (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Financial Status Indicator	C
Price	\$74.03
Change (%)	▼ 1.06 (1.41%)
Volume	179,060
52 Week Low	\$50.89
Market Cap	\$4,704,509,395
Rolling EPS	1.54
PE Ratio	48.8178
Shares Outstanding	62,651,610
Data as of 09/25/17 4:00 p.m. ET	



## NEWS & EVENTS

Date	Title
------	-------

There are currently no events scheduled.

08/14/17	PRA Health Sciences Announces Appointment of New Director
08/09/17	PRA Health Sciences, Inc. Announces Pricing of Secondary Offering of 10,000,000 Shares of Common Stock
08/08/17	PRA Health Sciences, Inc. Announces Secondary Offering of 10,000,000 Shares of Common Stock

## SEC FILINGS

Filing Date	Form
09/11/17	8-K
09/05/17	8-K
08/31/17	4
08/31/17	4

## BOARD OF DIRECTORS

Colin Shannon	Chairman of the Board
Jeffrey T. Barber	Director
Alexander G. Dickinson	Director
Linda S. Grais, M.D.	Director
Max C. Lin	Director
James C. Momtazee	Director
Ali J. Satvat	Director
Matthew P. Young	Director

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)